News Desk, AnyTV, New Delhi
Published by: Amit Mandal
Updated Wed, 09 Mar 2022 05:31 PM IST
Summary
The DCGI on February 21 allowed limited use of the biological E’s COVID-19 vaccine Corbevax for the age group below 12 to 18 years under certain conditions.
hear the news
Expansion
SII study on 2707 children
The government has not yet taken any decision on vaccinating adolescents below 15 years of age. The Ministry of Health has consistently said that the need for vaccination and the inclusion of more people in the vaccination campaign is constantly reviewed. On February 21, Prakash Kumar Singh, Director (Government and Regulatory Affairs) at SII, said in the EUA application to DCGI that two studies on approximately 2707 children aged 12 to 17 years showed that Kovovax is highly efficacious, immunosuppressive and safe. .
An official source said that Singh has stated in his application – this approval will not only be beneficial for our country, but will benefit the entire world. It will also fulfill our Prime Minister’s vision of ‘Making in India for the world’. In line with the vision of our CEO Dr. Adar C Poonawalla, I am sure that Kovovax will play a vital role in saving the children of our country and the world at large from COVID-19 and will keep our national flag flying high globally.
Kovovax has been approved for emergency use in adults
The DCGI has already approved Kovovax for limited use in emergency situations in adults on December 28. It has not yet been included in the country’s vaccination campaign. The DCGI on February 21 allowed limited use of the biological E’s COVID-19 vaccine Corbevax for the age group below 12 to 18 years under certain conditions.
Kovovax is manufactured by transfer of technology from Novavax and is approved by the European Medicines Agency for conditional marketing permission. Emergency use list has also been provided by WHO as on December 2017. Bharat Biotech’s Covaxin is being used to vaccinate adolescents between 15-18 years of age in the country.